Johanna Tommiska

List of Publications by Year
in descending order

61	7,563	94433	128289
papers	citations	37 h-index	60 g-index

61	61	61	9925
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	InÂvitro reconstitution reveals cooperative mechanisms of adapter protein-mediated activation of phospholipase C-Î³1 in T cells. Journal of Biological Chemistry, 2022, 298, 101680.	3.4	5
2	Activating Adenosine Monophosphateâ€“Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice. Hepatology, 2021, 73, 2206-2222.	7.3	43
3	Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. Nature Communications, 2021, 12, 7256.	12.8	32
4	Neuron-Derived Neurotrophic Factor Is Mutated in Congenital Hypogonadotropic Hypogonadism. American Journal of Human Genetics, 2020, 106, 58-70.	6.2	39
5	Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nature Reviews Rheumatology, 2020, 16, 547-564.	8.0	81
6	Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling. Journal of Experimental and Clinical Cancer Research, 2020, 39, 276.	8.6	14
7	FGF6 and FGF9 regulate UCP1 expression independent of brown adipogenesis. Nature Communications, 2020, 11, 1421.	12.8	67
8	Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nature Chemical Biology, 2020, 16, 267-277.	8.0	31
9	A Conserved Allosteric Pathway in Tyrosine Kinase Regulation. Structure, 2019, 27, 1308-1315.e3.	3.3	16
10	Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. EBioMedicine, 2019, 48, 462-477.	6.1	17
11	A G proteinâ€“coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23. JCI Insight, 2019, 4, .	5.0	16
12	Î±-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature, 2018, 553, 461-466.	27.8	348
13	Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney International, 2018, 93, 95-109.	5.2	117
14	Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Scientific Reports, 2018, 8, 15973.	3.3	12
15	Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB Journal, 2018, 32, 3752-3764.	0.5	85
16	A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. F1000Research, 2018, 7, 872.	1.6	52
17	Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. Journal of Bone and Mineral Research, 2017, 32, 2062-2073.	2.8	22
18	A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration. Cardiovascular Research, 2017, 113, 1585-1602.	3.8	23

#	Article	IF	Citations
19	<scp>KLB</scp> , encoding Î²â€Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. EMBO Molecular Medicine, 2017, 9, 1379-1397.	6.9	77
20	Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell Reports, 2017, 20, 1717-1728.	6.4	71
21	Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. Structure, 2017, 25, 1325-1336.e3.	3.3	25
22	Two missense mutations in KCNQ1 cause pituitary hormone deficiency and maternally inherited gingival fibromatosis. Nature Communications, 2017, 8, 1289.	12.8	33
23	Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. ELife, 2017, 6, .	6.0	38
24	Î²-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight, 2017, 2, .	5.0	41
25	Gonadotropin-releasing hormone receptor mutations in ageing men. Clinical Endocrinology, 2016, 84, 150-151.	2.4	1
26	Fibulin-1 Binds to Fibroblast Growth Factor 8 with High Affinity. Journal of Biological Chemistry, 2016, 291, 18730-18739.	3.4	10
27	Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Scientific Reports, 2016, 6, 31026.	3.3	58
28	Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene. Scientific Reports, 2016, 6, 32819.	3.3	42
29	Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase CÎ³. Molecular Cell, 2016, 61, 98-110.	9.7	48
30	Childhood growth in boys with congenital hypogonadotropic hypogonadism. Pediatric Research, 2016, 79, 705-709.	2.3	19
31	FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. Journal of Lipid Research, 2015, 56, 1481-1491.	4.2	83
32	A missense mutation in MKRN3 in a Danish girl with central precocious puberty and her brother with early puberty. Pediatric Research, 2015, 78, 709-711.	2.3	38
33	Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. Genetics in Medicine, 2015, 17, 651-659.	2.4	55
34	The demonstration of Î±Klotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrology Dialysis Transplantation, 2015, 30, 223-233.	0.7	124
35	De novo SOX10 nonsense mutation in a patient with Kallmann syndrome and hearing loss. Pediatric Research, 2014, 76, 115-116.	2.3	31
36	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4869-77.	7.1	154

#	Article	IF	Citations
37	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Molecular Cell, 2014, 53, 534-548.	9.7	247
38	Genetics of congenital hypogonadotropic hypogonadism in Denmark. European Journal of Medical Genetics, 2014, 57, 345-348.	1.3	30
39	Mutation screening of SEMA3A and SEMA7A in patients with congenital hypogonadotropic hypogonadism. Pediatric Research, 2014, 75, 641-644.	2.3	64
40	Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding. Diabetes, 2014, 63, 4057-4063.	0.6	467
41	Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature, 2014, 513, 436-439.	27.8	201
42	Exploring mechanisms of FGF signalling through the lens of structural biology. Nature Reviews Molecular Cell Biology, 2013, 14, 166-180.	37.0	449
43	Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in Individuals with Congenital Hypogonadotropic Hypogonadism. American Journal of Human Genetics, 2013, 92, 725-743.	6.2	227
44	PROKR2 mutations in autosomal recessive Kallmann syndrome. Fertility and Sterility, 2013, 99, 815-818.	1.0	20
45	Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion. PLoS Genetics, 2013, 9, e1003975.	3.5	139
46	Reversible Congenital Hypogonadotropic Hypogonadism in Patients with CHD7, FGFR1 or GNRHR Mutations. PLoS ONE, 2012, 7, e39450.	2.5	81
47	Incidence, Phenotypic Features and Molecular Genetics of Kallmann Syndrome in Finland. Orphanet Journal of Rare Diseases, 2011, 6, 41.	2.7	147
48	LIN28B, LIN28A, KISS1, and KISS1R in idiopathic central precocious puberty. BMC Research Notes, 2011, 4, 363.	1.4	43
49	LIN28B in Constitutional Delay of Growth and Puberty. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3063-3066.	3.6	47
50	Impaired Fibroblast Growth Factor Receptor 1 Signaling as a Cause of Normosmic Idiopathic Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4380-4390.	3.6	82
51	Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. Journal of Clinical Investigation, 2008, 118, 2822-2831.	8.2	348
52	Tissue-specific Expression of Î²Klotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21. Journal of Biological Chemistry, 2007, 282, 26687-26695.	3.4	654
53	ATM variants and cancer risk in breast cancer patients from Southern Finland. BMC Cancer, 2006, 6, 209.	2.6	23
54	Evaluation ofRAD50 in familial breast cancer predisposition. International Journal of Cancer, 2006, 118, 2911-2916.	5.1	51

#	Article	IF	Citations
55	Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6281-6286.	7.1	225
56	The FGF signaling pathway and human disease. FASEB Journal, 2006, 20, A694.	0.5	0
57	A protein canyon in the FGFâ€“FGF receptor dimer selects from an Ã la carte menu of heparan sulfate motifs. Current Opinion in Structural Biology, 2005, 15, 506-516.	5.7	132
58	Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival. Clinical Cancer Research, 2005, 11, 5098-5103.	7.0	138
59	Structural basis for fibroblast growth factor receptor activation. Cytokine and Growth Factor Reviews, 2005, 16, 107-137.	7.2	625
60	Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Human Molecular Genetics, 2004, 13, 2313-2324.	2.9	131
61	Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. Molecular Cell, 2000, 6, 743-750.	9.7	1,024